STAT+: Democrats take new step toward investigating Trump’s drug pricing deals
WASHINGTON — The incoming Democratic chairs of key committees have taken a new step toward investigating the most-favored nation drug pricing agreements between drugmakers and the Trump administration.
Key points
- Since then, additional companies have signed agreements with the Trump administration.
- Continue to STAT+ to read the full story….
- A new round of letters were recently sent to all 27 companies, according to a congressional source familiar with the letters.
The drug pricing deals are expected to be a top health care oversight priority for Democrats once they take the majority in January.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.